EuroBiotech: More Articles of Note

In our EuroBiotech roundup this week, Vantia hits goal in phase 3, Celyad posts glance at CAR-T data and Heptares co-founder bags Nobel Prize.

> RedHill Biopharma talked up its prospects of moving Bekinda into phase 3 after posting top-line data from a mid-stage study. But with the primary endpoint brushing the barrier of success with a p value of 0.05, shares in the Israeli biotech fell 13% on the back of the news. RedHill plans to discuss the data with FDA early next year with a view to moving into a pivotal study. Statement

> A patient with relapsed refractory acute myeloid leukemia experienced a complete response after treatment with Celyad’s CAR-T. The response was achieved without the use of chemotherapy preconditioning in one of the three patients in the first dose level of Celyad’s early-phase trial. Release

> A phase 3 trial of Vantia Therapeutics’ fedovapagon in men with benign prostatic hyperplasia met its primary endpoint. The study assessed the effect of fedovapagon on the participants’ need to urinate in the night, chalking up a statistically-significant improvement over placebo. The trial also met a quality-of-life co-primary endpoint and a clutch of secondary goals. Ferring Research-spinout Vantia now plans to run a second phase 3 trial with the same endpoints to support filings for approval. Statement

> Transgene and Randox teamed up to develop oncolytic immunotherapies against solid tumors. The alliance combines Transgene’s viral platform and Randox’s single-domain antibodies. Release

> Heptares co-founder Richard Henderson shared the Nobel Prize in Chemistry with two other scientists. Henderson received the award for his work on cryo-electron microscopy. Statement 

> Faron Pharmaceuticals proposed to raise £10 million. Some of the cash will go toward development of Faron’s cancer candidate Clevegen. Release